Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Signed informed consent;
Age of 18 or above;
Histology confirmed locally advanced unresectable or metastatic triple-negative breaset cancer;
(KN046 monotherapy) failed at least one prior anthracycline and taxane containing systemic treatment, (KN046 plus nab-paclitaxel) systemic treatment naive;
Measurable disease at baseline;
ECOG 0-1;
Adequate organ functions.
You may not be if
Untreated active CNS metastasis or leptomeningeal metastasis;
Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment;
Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;
Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent; History of uncontrolled intercurrent illness; Known severe hypersensitivity reactions to antibody drug.
Clareo Health | A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast Cancer
